Patents by Inventor Juliana M. Layzer
Juliana M. Layzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150344533Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: ApplicationFiled: November 13, 2014Publication date: December 3, 2015Inventors: JULIANA M. LAYZER, CHRISTOPHER P. RUSCONI, DOUGLAS BROOKS, STEVEN ZELENKOFSKE
-
Patent number: 8889645Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: GrantFiled: November 7, 2012Date of Patent: November 18, 2014Assignee: Regado Biosciences, Inc.Inventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven Zelenkofske
-
Patent number: 8889646Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: GrantFiled: November 7, 2012Date of Patent: November 18, 2014Assignee: Regado Biosciences, Inc.Inventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven Zelenkofske
-
Publication number: 20140128454Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: ApplicationFiled: November 7, 2012Publication date: May 8, 2014Applicant: REGADO BIOSCIENCES, INC.Inventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven Zelenkofske
-
Publication number: 20140128587Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: ApplicationFiled: November 7, 2012Publication date: May 8, 2014Applicant: REGADO BIOSCIENCES, INC.Inventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven Zelenkofske
-
Patent number: 8367627Abstract: Focused aptamer libraries are constructed in accordance with a proteome (i.e., complex mixture of native biomolecules). The libraries may be screened to identify one or more candidate aptamers with desired biological activities other than specific binding to a target. Aptamers which are selected or derivatives thereof may be used for those specific activities in biological systems. Any combination of deconvoluting a focused library (functional profiling), increasing frequencies of particular aptamers in a focused library (Laser SELEX), and decreasing frequencies of particular aptamers in a focused library (DeSELEX) may be performed prior to assaying biological activity.Type: GrantFiled: September 15, 2006Date of Patent: February 5, 2013Assignee: Duke UniversityInventors: Bruce A. Sullenger, Juliana M. Layzer, Christopher P. Rusconi, Sabah Oney, Nanette L. S. Que-Gewirth
-
Patent number: 8318923Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: GrantFiled: June 3, 2010Date of Patent: November 27, 2012Assignee: Regado Biosciences, Inc.Inventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven L. Zelenkofske
-
Publication number: 20120095085Abstract: Provided are ligands which bind to and regulate the function of CLEC-2. Nucleic acid CLEC-2 ligands described herein are able to inhibit CLEC-2 mediated platelet aggregation and may also provide use in regulating CLEC-2-mediated processes such as thrombus formation, tumor metastasis, lymphangiogenesis, HIV dissemination, inflammatory response, cytokine production and phagocytosis. Also disclosed herein are modulator molecules which can reverse the activity of the CLEC-2 ligand both in vitro and in vivo and ex vivo.Type: ApplicationFiled: October 14, 2011Publication date: April 19, 2012Inventors: JULIANA M. LAYZER, Sanjoy K. Mahanty, Samuel C. Wolff, Catherine C. Redick, Christopher P. Rusconi
-
Publication number: 20100311820Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.Type: ApplicationFiled: June 3, 2010Publication date: December 9, 2010Applicant: Regado Biosciences, IncInventors: Juliana M. Layzer, Christopher P. Rusconi, Douglas Brooks, Steven L. Zelenkofske
-
Publication number: 20090264508Abstract: Focused aptamer libraries are constructed in accordance with a proteome (i.e., complex mixture of native biomolecules). The libraries may be screened to identify one or more candidate aptamers with desired biological activities other than specific binding to a target. Aptamers which are selected or derivatives thereof may be used for those specific activities in biological systems. Any combination of deconvoluting a focused library (functional profiling), increasing frequencies of particular aptamers in a focused library (Laser SELEX), and decreasing frequencies of particular aptamers in a focused library (DeSELEX) may be performed prior to assaying biological activity.Type: ApplicationFiled: September 15, 2006Publication date: October 22, 2009Inventors: Bruce A. Sullenger, Juliana M. Layzer, Christopher P. Rusconi, Sabah Oney, Nanette L.S. Que-Gewirth